Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $916000.0.

  • Serina Therapeutics' Non-Current Assets fell 5447.32% to $916000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 4497.24%. This contributed to the annual value of $1.0 million for FY2024, which is 2231.28% down from last year.
  • Per Serina Therapeutics' latest filing, its Non-Current Assets stood at $916000.0 for Q3 2025, which was down 5447.32% from $950000.0 recorded in Q2 2025.
  • Serina Therapeutics' 5-year Non-Current Assets high stood at $11.1 million for Q3 2023, and its period low was $788000.0 during Q4 2022.
  • Its 5-year average for Non-Current Assets is $2.7 million, with a median of $985000.0 in 2021.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 124823.39% in 2023, then plummeted by 8360.94% in 2024.
  • Over the past 5 years, Serina Therapeutics' Non-Current Assets (Quarter) stood at $920000.0 in 2021, then fell by 14.35% to $788000.0 in 2022, then skyrocketed by 71.19% to $1.3 million in 2023, then dropped by 22.31% to $1.0 million in 2024, then decreased by 12.6% to $916000.0 in 2025.
  • Its last three reported values are $916000.0 in Q3 2025, $950000.0 for Q2 2025, and $977000.0 during Q1 2025.